BIS010 is a semi-synthetic plant origin polysaccharide demonstrating a potential modifying effect of the biologic activity of the joints.

Pre-clinical tests show that BIS010 delays cartilage degeneration and displays anti-inflammatory activity by reducing pro-inflammatory molecules, assisting repair of damaged joints

Osteoarthritis is one of the most prevalent diseases of industrialized countries, believed to be affecting 16% of their population and forecasted to grow steadily to reach $7 billion by 2015.

Current most popular treatments target symptomatic effects of the disease such as NSAIDS and COX-2 inhibitors. However these products have no disease modifying properties and a history of side effects which has lead to several molecule withdrawals in the last years.

Experimental data has shown the ability of BIS010 to balance the metabolism of osteoarthritic cartilage by acting on the synthesis and turnover of a number of important compounds in the extracellular matrix of connective tissues. BIS010 has also shown an anti-inflammatory effect on the main parameters considered in the inflammation procedure.

Research data at this preliminary state, seems  to characterize BIS010 as a symptomatic slow-acting drug for osteoarthritis (SYSADOA) and  has shown to have a better efficacy at substantial lower doses than Chondroitin Sulphate, one of the most used SYSADOA drugs currently in the market.

BIS010 has demonstrated possible osteoarthritis modifying properties by providing a protective effect of cartilage integrity. Therefore, BIS010 could also act as a structure disease-modifying osteoarthritis drug (S/DMOAD).

At this step BIS010 has demonstrated to be completely safe in the in vitro and in vivo models studied.

There is strong evidence to speculate that BIS010 could be indicated for the treatment of chronic inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and potentially others (psoriasis, Crohn’s disease, asthma and ulcerative colitis).  

Early Stage

Spanish application filed on 27/02/2004 and priority filings for USA, Japan, Canada, Australia, New Zealand and Europe under title “New therapeutic use for a group of sulphated polysaccharides”

Spanish patent number 200400464 (27-2-2004)
International Publication Number   WO 2005/084610 A2
Patent application PCT      PCT/EP2005/001390  

Bioiberica’s goal is to actively seek a partnership with a company interested in musculoskeletal diseases to complete the clinical development.

Bioiberica is willing to consider an exclusive licensing agreement and will offer its extensive know-how on clinical development of chondroprotectors and manufacturing of sulphated polysaccharides